ES2547687T3 - Forma cristalina I de sal de un inhibidor de dipeptidil-peptidasa IV y procedimiento de preparación y uso de la misma - Google Patents

Forma cristalina I de sal de un inhibidor de dipeptidil-peptidasa IV y procedimiento de preparación y uso de la misma Download PDF

Info

Publication number
ES2547687T3
ES2547687T3 ES12812010.2T ES12812010T ES2547687T3 ES 2547687 T3 ES2547687 T3 ES 2547687T3 ES 12812010 T ES12812010 T ES 12812010T ES 2547687 T3 ES2547687 T3 ES 2547687T3
Authority
ES
Spain
Prior art keywords
crystalline form
salt
inhibitor
preparation
dipeptidyl peptidase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES12812010.2T
Other languages
English (en)
Inventor
Chutian Shu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shandong Xuanzhu Pharma Co Ltd
Original Assignee
Xuanzhu Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xuanzhu Pharma Co Ltd filed Critical Xuanzhu Pharma Co Ltd
Application granted granted Critical
Publication of ES2547687T3 publication Critical patent/ES2547687T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Forma cristalina I de la sal dihidrocloruro del compuesto (R)-2-[[7-(3-aminopiperidín-1-il)-3,5-dimetil-2-oxo-2,3- dihidro-1H-imidazo[4,5-b]piridín-1-il]metil]benzonitrilo representado por la fórmula (1), caracterizada por que presenta sus picos característicos en 8,7±0,2º, 19,4±0,2º, 23,5±0,2º y 27,2±0,2º en la difracción de rayos X de los polvos indicada por un ángulo 2θ (º) utilizando radiación Kα de Cu,**Fórmula**

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6

Claims (1)

  1. imagen1
    imagen2
ES12812010.2T 2011-07-09 2012-07-06 Forma cristalina I de sal de un inhibidor de dipeptidil-peptidasa IV y procedimiento de preparación y uso de la misma Active ES2547687T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201110202157 2011-07-09
CN201110202157 2011-07-09
PCT/CN2012/078294 WO2013007167A1 (zh) 2011-07-09 2012-07-06 二肽基肽酶-iv抑制剂的盐的晶型i及其制备方法和应用

Publications (1)

Publication Number Publication Date
ES2547687T3 true ES2547687T3 (es) 2015-10-08

Family

ID=47442601

Family Applications (1)

Application Number Title Priority Date Filing Date
ES12812010.2T Active ES2547687T3 (es) 2011-07-09 2012-07-06 Forma cristalina I de sal de un inhibidor de dipeptidil-peptidasa IV y procedimiento de preparación y uso de la misma

Country Status (6)

Country Link
US (1) US8927572B2 (es)
EP (1) EP2730575B1 (es)
JP (1) JP5695800B2 (es)
CN (1) CN102863440B (es)
ES (1) ES2547687T3 (es)
WO (1) WO2013007167A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108602817B (zh) * 2015-12-24 2020-12-25 吉林惠升生物制药有限公司 二肽基肽酶-iv抑制剂的苯甲酸盐的晶型
WO2017211293A1 (zh) * 2016-06-08 2017-12-14 山东轩竹医药科技有限公司 二肽基肽酶-iv抑制剂的丁二酸盐的晶型

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY28103A1 (es) 2002-12-03 2004-06-30 Boehringer Ingelheim Pharma Nuevas imidazo-piridinonas sustituidas, su preparación y su empleo como medicacmentos
AU2003302657B8 (en) * 2002-12-04 2009-12-03 Eisai R&D Management Co., Ltd. Fused 1,3-dihydroimidazole ring compounds
CN101228164A (zh) 2005-05-20 2008-07-23 布里斯托尔-迈尔斯·斯奎布公司 二肽基肽酶iv的吡咯并吡啶类抑制剂及方法
US7521557B2 (en) * 2005-05-20 2009-04-21 Bristol-Myers Squibb Company Pyrrolopyridine-based inhibitors of dipeptidyl peptidase IV and methods
CA2713864A1 (en) * 2008-02-04 2009-08-13 Cytokinetics, Incorporated Certain chemical entities, compositions and methods
AR074072A1 (es) * 2008-11-11 2010-12-22 Lilly Co Eli Compuesto de imidazol -piperidin -pirrol-pirimidin-6-ona, composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para tratar el glioblastoma multiforme
CN102127070A (zh) 2010-01-15 2011-07-20 山东轩竹医药科技有限公司 吡啶并环衍生物

Also Published As

Publication number Publication date
US8927572B2 (en) 2015-01-06
JP5695800B2 (ja) 2015-04-08
EP2730575A1 (en) 2014-05-14
EP2730575A4 (en) 2014-11-26
CN102863440B (zh) 2015-05-27
EP2730575B1 (en) 2015-09-16
WO2013007167A1 (zh) 2013-01-17
HK1192231A1 (en) 2014-08-15
CN102863440A (zh) 2013-01-09
JP2014520763A (ja) 2014-08-25
US20140206874A1 (en) 2014-07-24

Similar Documents

Publication Publication Date Title
PE20141406A1 (es) 4-(8-metoxi-1-((1-metoxipropan-2-il)-2-(tetrahidro-2h-piran-4-il)-1h-imidazo[4,5-c]quinolin-7-il)-3,5-dimetilisoxazol y su uso como inhibidor bromodominio
CL2014000343A1 (es) Procedimientos de preparacion de compuesto polimorfico derivado de pirazolo[3,4-d]pirimidina; sal del compuesto; composicion farmaceutica que lo comprende y su uso en el tratamiento de un trastorno asociado a mtor.
ZA201903184B (en) Compositions, methods, and systems for the synthesis and use of imaging agents
CL2016001537A1 (es) Inhibidores de syk
EA201491456A1 (ru) Соединения-ингибиторы raf
PE20120083A1 (es) Sal monotosilato del compuesto 2-metil-2-[4-(3-metil-2-oxo-8-quinolin-3-il-2, 3-dihidro-imidazo-[4,5-c]-quinolin-1-il)-fenil]-propionitrilo en su forma cristalina a
MX2019003605A (es) Formas solidas de un inhibidor de cdk4/6 selectivo.
CL2012002318A1 (es) Compuestos derivados de tieno [2,3-d]pirimidina, inhibidores de quinasa mnk1 y mnk2; composición farmaceutica; que los comprende; y su uso en el tratamiento de enfermedades metabolicas, hematopoyeticas, neurodegenerativas, renales, inflamatorias y cancer.
CL2013002821A1 (es) Compuestos derivados de pirrolo[2,3-d]pirimidina; composicion farmaceutica que los comprende; y su uso como antagonista de los receptores tropomiosina (trk) para el tratamiento del dolor.
CL2013003051A1 (es) Compuestos derivados de pirazolo (4.3-d) pirimidinas, inhibidores de quinasa; composicion farmaceutica; y uso para el tratamiento de enfermedades y trastornos del aparato respiratorio
ZA200901477B (en) Pyrido (2,3-D) pyrimidinone compounds and their use as PI3 inhibitors
MY148469A (en) Spiro-ring compound and use thereof for medical purposes
SA515360469B1 (ar) مركبات حلقية غير متجانسة لتثبيط إنزيم جلوتاميناز والطرق الخاصة باستخدامها
IL228561A0 (en) Converted 3,2-dihydroimidazo[2,1-c]quinazoline salts
SI3077397T1 (sl) 2-amino-6-fluoro-N-(5-fluoro-piridin-3-IL)pirazolo(1,5-A)pirimidin-3- karboksamidna spojina, koristna kot inhibitor kinaze ATR, njena priprava, različne trdne oblike in njeni radioaktivno označeni derivati
TN2018000087A1 (en) New pyrrolo[2,3-d]pyrimidine derivatives as dual dyrk1/clk1 inhibitors
IL229178B (en) Pyruvate kinase activating compounds for use in the treatment of disease
ES2620754T3 (es) Uso de 5-androstano (alquil)-3,5,6-triol en la preparación de fármacos neuroprotectores
EP2881384A8 (en) Partially saturated nitrogen-containing heterocyclic compound
LT3088401T (lt) (6s,9as)-n-benzil-6-((4-hidroksifenil)metil)-4,7-diokso-8-((6-(3-(piperazin-1-il)azetidin-1-il)piridin-2-il)metil)-2-(prop-2-en-1-il)-oktahidro-1h-pirazino(2,1-c)(1,2,4)triazin-1-karboksamido junginys
PH12015501993A1 (en) Pyrazole-amide compound and medicinal uses therefor
AR077203A1 (es) Forma polimorfica d del acetato de bazedoxifeno, composiciones farmaceuticas que la contienen metodo para prepararla y uso del mismo para tratar enfermedades mediadas por moduladores selectivos de receptores estrogenicos (serms)
EP2739627A4 (en) 2,3-DIHYDROIMIDAZO- [1,2-C-] PYRIMIDIN-5 (1H) -ONE COMPOUNDS AS LP-PLA² INHIBITORS
CL2013003044A1 (es) Compuestos derivados de [1,2,4]triazolo[1,5-a]piridina, inhibidores de quinasa mps-1; composicion farmaceutica; procedimiento de preparacion; combinacion farmaceutica; compuestos intermediarios; y uso para la profilaxis o tratamiento de un tumor hematologico, un tumor solido y/o sus metastasis y leucemias, entre otras enfermedades.
NI200900183A (es) Compuestos de pirido [2,3-d] pirimidina - 7 - ona como inhibidores de pi3k - alfa para el tratamiento del cáncer.